Sedegah, Martha, Rogers, William O., Belmonte, Arnel, Belmonte, Maria, Banania, Glenna, Patterson, Noelle, Ferrari, Marilyn, Kaslow, David C., Carucci, Daniel J., Richie, Thomas L., and Doolan, Denise L. (2006) Vaxfectin™ enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine, 24 (11). pp. 1921-1927.

PDF (Published Version) - Published Version Restricted to Repository staff only

Abstract

We evaluated the capacity of the cationic lipid based formulation, Vaxfectin™, to enhance the immunogenicity and protective efficacy of DNA-based vaccine regimens in the Plasmodium yoelii murine malaria model. We immunized Balb/c mice with varying doses (0.4–50 μg) of plasmid DNA (pDNA) encoding the P. yoelii circumsporozoite protein (PyCSP), either in a homologous DNA/DNA regimen (D-D) or a heterologous prime-boost DNA-poxvirus regimen (D-V). At the lowest pDNA doses, Vaxfectin™ substantially enhanced IFA titers, ELISPOT frequencies, and protective efficacy. Clinical trials of pDNA vaccines have often used low pDNA doses based on a per kilogram weight basis. Formulation of pDNA vaccines in Vaxfectin™ may improve their potency in human clinical trials.

Item ID:	42751
Item Type:	Article (Research - C1)
ISSN:	1873-2518
Keywords:	malaria; T-lymphocytes; plasmid DNA (pDNA) vaccines
Funders:	Naval Medical Research and Development Command (NMRDC), CRADA with Vical Inc. (CRADA-VI)
Projects and Grants:	NMRDC 61102A3M161102.BS13 AK111, NMRDC 62787A 3M162787.A870 AN121, (CRADA-VI) Agreement Number: NCRADA-NMRC-03-1561
Date Deposited:	21 Mar 2016 22:51
FoR Codes:	11 MEDICAL AND HEALTH SCIENCES > 1107 Immunology > 110799 Immunology not elsewhere classified @ 100%
SEO Codes:	92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920109 Infectious Diseases @ 100%
Downloads:	Total: 2
	More Statistics